ReviewMolecular biotechnology2015
Carrot cells: a pioneering platform for biopharmaceuticals production.
Review in Molecular biotechnology, 2015. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 20 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
20 citing papers in PubMed, 60 citations in OpenAlex.
- Recombinant Protein Drugs: A 2025 Update.BioDrugs : clinical immunotherapeutics, biopharmaceuticals and gene therapy · 2026Review
- Molecular Pharming: Advances, Applications, and Future Prospects in Biotechnology and Medicine.Engineering in life sciences · 2026Review
- Article
- Trends and Challenges in Plant Cryopreservation Research: A Meta-Analysis of Cryoprotective Agent Development and Research Focus.Plants (Basel, Switzerland) · 2025Review
- Bioactive Potential of Carrot-Based Products Enriched withMolecules (Basel, Switzerland) · 2024Article
- Plant-made pharmaceuticals: exploring studies for the production of recombinant protein in plants and assessing challenges ahead.Plant biotechnology reports · 2023Review
- Three Parts of the Plant Genome: On the Way to Success in the Production of Recombinant Proteins.Plants (Basel, Switzerland) · 2022Review
- Article
- Plant-Based Innovations for the Transition to Sustainability: A Bibliometric and in-Depth Content Analysis.Foods (Basel, Switzerland) · 2022Review
- Plant-made poliovirus vaccines - Safe alternatives for global vaccination.Frontiers in plant science · 2022Review
- Origin, evolution, breeding, and omics of Apiaceae: a family of vegetables and medicinal plants.Horticulture research · 2022Article
- Review
- Plant Platforms for Efficient Heterologous Protein Production.Biotechnology and bioprocess engineering : BBE · 2021Review
- Role ofMolecules (Basel, Switzerland) · 2020Article
- Development of Systems for the Production of Plant-Derived Biopharmaceuticals.Plants (Basel, Switzerland) · 2019Review
- Improved recombinant protein production in Arabidopsis thaliana.Plant signaling & behavior · 2018Article
- Corn-based vaccines: current status and prospects.Planta · 2017Review
- The Last Ten Years of Advancements in Plant-Derived Recombinant Vaccines against Hepatitis B.International journal of molecular sciences · 2016Review
- Article
- Putting the Spotlight Back on Plant Suspension Cultures.Frontiers in plant science · 2016Review
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
2 authors at 1 institution in 1 country.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Carrot (Daucus carota L.) is of importance in the molecular farming field as it constitutes the first plant species approved to produce biopharmaceuticals for human use. In this review, features that make carrot an advantageous species in the molecular farming field are analyzed and a description of the developments achieved with this crop thus far is presented. A guide for genetic transformation procedures is also included. The state of the art comprises ten vaccine prototypes against Measles virus, Hepatitis B virus, Human immunodeficiency virus, Yersinia pestis, Chlamydia trachomatis, Mycobacterium tuberculosis, enterotoxigenic Escherichia coli, Corynebacterium diphtheria/Clostridium tetani/Bordetella pertussis, and Helicobacter pylori; as well as the case of the glucocerebrosidase, an enzyme used for replacement therapy, and other therapeutics. Perspectives for these developments are envisioned and innovations are proposed such as the use of transplastomic technologies-, hairy roots-, and viral expression-based systems to improve yields and develop new products derived from this advantageous plant species.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.